Immunohistochemistry in the diagnosis of cutaneous neoplasms

Future Oncology

Volumn 6, Issue 1, 2010, Pages 93-109

  Hoang, Mai P ^a   Mahalingam, Meera ^b   Selim, M Angelica ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Adnexal neoplasm; Cutaneous neoplasm; Dermatopathology; Histiocytic neoplasm; Immunohistochemistry; Lymphoid neoplasm; Melanocytic neoplasms; Spindle cell neoplasms

Indexed keywords

APOLIPOPROTEIN D; BLOOD CLOTTING FACTOR 13A; CD23 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD68 ANTIGEN; CD99 ANTIGEN; CYTOKERATIN 15; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 903; GLUCOSE TRANSPORTER 1; GROSS CYSTIC DISEASE FLUID PROTEIN 15; KI 67 ANTIGEN; MISMATCH REPAIR PROTEIN PMS2; MONOCLONAL ANTIBODY D2-40; MONOCLONAL ANTIBODY HMB 45; NERVE GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P21; PROTEIN P63; PROTEIN P75; PROTEIN S 100; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR FLI 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADNEXAL NEOPLASM; ATYPICAL FIBROXANTHOMA; BASAL CELL CARCINOMA; BLUE NEVUS; CAPSULAR NEVUS; COMPARATIVE STUDY; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; DERMOPLASTIC MELANOMA; DESMOPLASTIC TRICHOEPTHELIOMA; DIFFERENTIAL DIAGNOSIS; DYSPLASTIC NEVUS; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE MELANOMA; MELANOCYTIC NEOPLASM; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; METASTASIS POTENTIAL; MICROCYTIC ADNEXAL CARCINOMA; MUSCLE TUMOR; NEVOID MELANOMA; PRIMARY ADNEXAL CARCINOMA; PRIORITY JOURNAL; REVIEW; SARCOMATOID SQUAMOUS CELL CARCINOMA; SCLEROSING NEOPLASM; SEBACEOUS NEOPLASM; SENSITIVITY AND SPECIFICITY; SKIN CANCER; SKIN SCAR; SPINDLE CELL; SPINDLE CELL MELANOMA; SPITZOID TUMOR; SQUAMOUS CELL CARCINOMA; SUPERFICIAL ACRAL FIBROMYXOMA; TRICHOEPITHELIOMA; VASCULAR TUMOR;

DERMATOLOGY; HUMANS; IMMUNOHISTOCHEMISTRY; PATHOLOGY, CLINICAL; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 75149162097     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.143     Document Type: Review

References (174)

1. Cho KH, Hashimoto K, Taniguchi Y et al.: Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66(4), 765-771 (1990).
2. Mangini J, Li N, Bhawan J: Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am. J. Dermatopathol. 24(3), 270-281 (2002).
3. Beltraminelli H, Shabrawi-Caelen LE, Kerl H, Cerroni L: Melan-a-positive 'pseudomelanocytic nests': a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sundamages skin. Am. J. Dermatopathol. 31(3), 305-308 (2009).
4. El Shabrawi-Caelen L, Kerl H, Cerroni L: Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am. J. Dermatopathol. 26(5), 364-366 (2004).
5. Wick MR, Swanson PE, Rocamora A: Recognition of malignant melanoma by monoclonal antibody HMB-45: an immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J. Cutan. Pathol. 15(4), 201-207 (1988).
6. Sundram U, Harvell JD, Rouse RV, Natkunam Y: Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod. Pathol. 16(8), 802-810 (2003).
7. Gown AM, Vogel AN, Hoak D et al.: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am. J. Pathol. 123(2), 195-203 (1986).
8. Sun J, Morton TH Jr, Gown AM: Antibody HMB-45 identifies the cells of blue nevi. An immunohistochemical study on paraffin sections. Am. J. Surg. Pathol. 14(8), 748-751 (1990).
9. Zubovits J, Buzney E, Yu L, Duncan LM: HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum. Pathol. 35(2), 217-223 (2004).
10. Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M: Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am. J. Surg. Pathol. 25(2), 205-211 (2001).
11. Rudolph R, Schubert C, Schubert B, Parwaresch R: Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J. Am. Acad. Dermatol. 37(2), 169-178 (1997).
12. McNutt NS, Urmacher C, Hakimian J, Hoss DM, Lugo J: Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J. Cutan. Pathol. 22(6), 502-517 (1995).
13. Prieto VG, Shea CR: Use of immunohistochemistry in melanocytic lesions. J. Cutan. Pathol. 35(Suppl. 2), 1-10 (2008). ■ A helpful review of melanocytic neoplasms.
14. Rothberg BEG, Moeder CB, Kluger H et al.: Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod. Pathol. 21(9), 1121-1129 (2008).
15. Kamino H, Tam S, Tapia B, Toussaint S: The use of elastin immunostain improves the evaluation of melanomas associated with nevi. J. Cutan. Pathol. 36(8), 845-852 (2009).
16. Chorny JA, Barr RJ: S100-positive spindle cells in scars: a diagnostic pitfall in the re-excision of desmoplastic melanoma. Am. J. Dermatopathol. 24(4), 309-312 (2002).
17. Radfar A, Stefanato CM, Ghosn S, Bhawan J: NGFR-positive desmoplastic melanomas with focal or absent S-100 staining: further evidence supporting the use of both NGFR and S-100 as a primary immunohistochemical panel for the diagnosis of desmoplastic melanomas. Am. J. Dermatopathol. 28(2), 162-167 (2006).
18. Kanik AB, Yaar M, Bhawan J: P75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J. Cutan. Pathol. 23(3), 205-210 (1996).
19. Hilliard NJ, Krahl D, Sellheyer K: P16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J. Cutan. Pathol. 36(7), 753-759 (2009).
20. Vollmer RT: Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am. J. Clin. Pathol. 122(4), 499-505 (2004).
21. Nasr MR, El-Zammar O: Comparison of PHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am. J. Dermatopathol. 30(2), 117-122 (2008).
22. Kapur P, Selim MA, Roy LC, Yegappan M, Weinberg AG, Hoang MP: Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical ana lysis. Mod. Pathol. 18(2), 197-204 (2005).
23. Ribe A, McNutt NS: S100A6 protein expression is different in Spitz nevi and melanomas. Mod. Pathol. 16(5), 505-511 (2003).
24. Carson KF, Wen DR, Li PX et al.: Nodal nevi and cutaneous melanoma. Am. J. Surg. Pathol. 20(7), 834-840 (1996).
25. Biddle DA, Evans HL, Kemp BL et al.: Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfalls with malignant melanoma and carcinoma. Am. J. Surg. Pathol. 27(5), 673-681 (2003).
26. Pages C, Rochaix P, al Saati T et al.: KBA.62: a useful marker for primary and metastatic melanomas. Hum. Pathol. 39(8), 1136-1142 (2008).
27. Folpe AL, Cooper K: Best practices in diagnostic immunohistochemistry: pleomorphic cutaneous spindle cell tumors. Arch. Pathol. Lab. Med. 131(10), 1517-1524 (2007). ■■ A good review of immunohistochemistry in the diagnosis of cutaneous spindle cell tumors.
28. Ko CJ, McNiff JM, Glusac EJ: Squamous cell carcinoma with single cell infiltration: a potential diagnostic pitfall and the utility of MNF116 and p63. J. Cutan. Pathol. 35(4), 353-357 (2008).
29. Gleason BC, Calder KB, Cibull TL et al.: Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J. Cutan. Pathol. 36(5), 543-547 (2009).
30. Dotto JE, Glusac EJ: P63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J. Cutan. Pathol. 33(6), 413-417 (2006).
31. Monteagudo C, Calduch L, Navarro S, Joan-Figueroa A, Llombart-Bosch A: CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am. J. Clin. Pathol. 117(1), 126-131 (2002).
32. Mirza B, Weedon D: Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas. J. Dermatol. 46(4), 235-238 (2005).
33. Hultgren TL, DiMaio DJ: Immunohistochemical staining of CD10 in atypical fibroxanthomas. J. Cutan. Pathol. 34(5), 415-419 (2007).
34. Luzar B, Calonje E: Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. J. Cutan. Pathol. (2009) (Epub ahead of print).
35. Jensen K, Wilkinson B, Wines N, Kossard S: Procollagen 1 expression in atypical fibroxanthoma and other tumors. J. Cutan. Pathol. 31(1), 57-61 (2004).
36. Goldblum JR, Tuthill RJ: CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am. J. Dermatopathol. 19(2), 147-153 (1997).
37. Li N, McNiff J, Hui P, Manfioletti G, Tallini G: Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor13a immunoreactivity. Am. J. Dermatopathol. 26(4), 267-272 (2004).
38. Erdag G, Qureshi HS, Patterson JW, Wick MR: CD34-positive dendritic cells disappear from scars but are increased in pericicatricial tissue. J. Cutan. Pathol. 35(8), 752-756 (2008).
39. Guillou L, Wadden C, Doindre J-M et al.: 'Proximal-type' epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features: clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am. J. Surg. Pathol. 21(2), 130-146 (1997).
40. Weiss SW, Nickoloff BJ: CD34 is expressed by a distinctive cell population in peripheral nerve, nerve sheath tumors, and related lesions. Am. J. Surg. Pathol. 17(10), 1039-1045 (1993).
41. Suster S, Fisher C: Immunoreactivity for the human hematopoietic progenitor cell antigen (CD34) in lipomatous tumors. Am. J. Surg. Pathol. 21(2), 195-200 (1997).
42. Okamura JM, Barr RJ, Battifora H: Solitary fibrous tumor of the skin. Am. J. Dermatopathol. 19(5), 515-518 (1997).
43. Schirren CG, Schirren H, Gyzicki-Nienhaus B et al.: Extra-abdominal fibromatosis: an immunohistochemical ana lysis. Hautarzt. 44(12), 789-794 (1993).
44. Shea CR, Salob S, Reed JA et al.: CD34-reactive fibrous papule of the nose. J. Am. Acad. Dermatol. 35(2 Pt 2), 342-345 (1996).
45. Lisovsky M, Hoang MP, Dresser KA, Kapur P, Bhawan J, Mahalingam M: Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Mod. Pathol. 21(1), 31-38 (2008).
46. Miettinen M, Lindenmayer AE, Chaubal A: Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y- antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod. Pathol. 7(1), 82-90 (1994).
47. McKenney JK, Weiss SW, Folpe AL: CD31 expression in intratumoral macrophages: a potential diagnostic pitfall. Am. J. Surg. Pathol. 25(9), 1167-1173 (2001).
48. Rossi S, Orvieto E, Furlanetto A, Laurino L, Ninfo V, Dei Tos AP: Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod. Pathol. 17(5), 547-552 (2004).
49. Patel RM, Goldblum JR, Hsi ED: Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. Mod. Pathol. 17(4), 456-460 (2004).
50. North PE, Waner M, Mizeracki A, Mihm MC Jr: GLUT-1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum. Pathol. 31(1), 11-22 (2000).
51. Leon-Villapalos J, Wolfe K, Kangesu L: GLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations. Br. J. Plast. Surg. 58(3), 348-352 (2005).
52. Picard A, Boscolo E, Zhan ZA et al.: IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinction and similarities between congenital and common infantile hemangioma. Pediatr. Research. 63(3), 263-267 (2008).
53. Fukunaga M: Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumors. Histopathology 46(6), 396-402 (2005).
54. Franke FE, Steger K, Marks A, Kutzner H, Mentzel T: Hobnail hemangiomas (targetoid hemosiderotic hemangiomas) are true lymphangiomas. J. Cutan. Pathol. 31(5), 362-367 (2004).
55. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G: A monoclonal antibody against a-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell. Biol. 103(6 Pt 2), 2787-2796 (1986).
56. Azumi N, Ben-Ezra J, Battifora H: Immunophenotypic diagnosis of leiomyosarcomas and rhabdomyosarcomas with monoclonal antibodies to muscle specific actin (MSA) and desmin in formalin fixed tissue. Mod. Pathol. 1(6), 469-474 (1988).
57. Lazarides E, Hubbard BD: Immunological characterization of the subunit of the 100 A filaments from muscle cells. Proc. Natl Acad. Sci. USA 73(12), 4344-4348 (1976).
58. Oliver GF, Reiman HM, Gonchoroff NJ et al.: Cutaneous and subcutaneous leiomyosarcoma: a clinical pathological review of 14 cases with reference to anti-desmin staining in nuclear DNA patterns studied by flow cytometry. Br. J. Dermatol. 124(3), 252-257 (1991).
59. South CD, Hampel H, Comeras I et al.: The frequency of Muir-Torre syndrome among Lynch syndrome families. J. Natl Cancer. Inst. 100(4), 277-281 (2008).
60. Orta L, Klimstra DS, Qin J et al.: Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am. J. Surg. Pathol. 33(6), 934-944 (2009).
61. Chhibber V, Dresser K, Mahalingam M: MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod. Pathol. 21(2), 159-164 (2008).
62. Popnikolov NK, Gatalica Z, Colombe-Grimmer MI et al.: Loss of mismatch repair proteins in sebaceous gland tumors. J. Cutan. Pathol. 30(3), 178-184 (2003).
63. Orta L, Klimstra DS, Qin J et al.: Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am. J. Surg. Pathol. 33(6), 934-944 (2009).
64. Cabral ES, Auerbach A, Killian JK, Barrett TL, Cassarino DS: Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry. Am. J. Dermatopathol. 28(6), 465-471 (2006).
65. Beer TW, Shepherd P, Theaker JM: Ber-EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology 37(3), 218-223 (2000).
66. Yu L, Galan A, McNiff JM: Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J. Cutan. Pathol. 36(10), 1074-1076 (2009).
67. Yada K, Kashima K, Daa T, Kitano S, Fujuwara S, Yokoyama S: Expression of CD10 in basal cell carcinoma. Am. J. Dermatopathol. 26(6), 463-471 (2004).
68. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C: CD10 expression in trichoepithelioma and basal cell carcinoma. J. Cutan. Pathol. 33(2), 123-128 (2006).
69. Katona TM, Perkins SM, Billings SD: Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/ infiltrative basal cell carcinoma? J. Cutan. Pathol. 35(2), 174-179 (2008).
70. Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M: Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod. Pathol. 21(2), 178-185 (2008).
71. Carvalho J, Fullen D, Lowe L, Su L, Ma L: The expression of CD23 in cutaneous non-lymphoid neoplasms. J. Cutan. Pathol. 34(9), 693-698 (2007).
72. Bogner PN, Su LD, Fullen DR: Cluster designation 5 staining of normal and non-lymphoid neoplastic skin. J. Cutan. Pathol. 32(1), 50-54 (2005).
73. Lyle S, Christofidou-Solomidou M, Liu Y, Elder DE, Albelda S, Cotsarelis G: The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human follicle stem cells. J. Cell. Sci. 111(Pt 21), 3179-3188 (1998).
74. Jih DM, Lyle S, Elenitsas R, Elder DE, Cotsarelis G: Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. J. Cutan. Pathol. 26(3), 113-118 (1999).
75. Krahl D, Sellheyer K: Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J. Cutan. Pathol. 34(10), 782-787 (2007).
76. Wallace ML, Longacre TA, Smoller BR: Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Mod. Pathol. 8(9), 897-901 (1995).
77. Qureshi HS, Ormsby AH, Lee MW, Zarbo RJ, Ma CK: The diagnostic utility of p63, CK5/6, CK7, and CK20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. J. Cutan. Pathol. 31(2), 145-152 (2004). ■ A helpful comparative study in the distinction of primary adnexal neoplasms versus cutaneous metastases.
78. Ivan D, Hafeez DA, Prieto VG et al.: Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J. Cutan. Pathol. 34(6), 474-480 (2007).
79. Kanitakis J, Chouvet B: Expression of p63 in cutaneous metastases. Am. J. Clin. Pathol. 128(5), 753-758 (2007).
80. Liang H, Wu H, Giorgadze TA et al.: Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am. J. Surg. Pathol. 31(2), 304-310 (2007). ■ Although not sensitive, D2-40 is a specific marker in distinguishing primary adnexal carcinomas from cutaneous metastases.
81. Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT: Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical ana lysis of 650 human neoplasms and comparison with a-lactalbumin. Hum. Pathol. 20(3), 281-287 (1989).
82. Wick M, Ockner DM, Mills SE, Ritter JH, Swanson PE: Homologous carcinomas of the breasts, skin and salivary glands: a histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma and salivary duct carcinoma. Am. J. Clin. Pathol. 109(1), 75-84 (1998).
83. Ansai S, Koseki S, Hozumi Y, Kondo S: An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation. Am. J. Dermatopathol. 17(3), 249-255 (1995).
84. Chu P, Wu D, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 13(9), 962-972 (2000).
85. Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch. Pathol. Lab. Med. 131(10), 1561-1567 (2007).
86. Ormsby AH, Snow JL, Su WP et al.: Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical ana lysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein. J. Am. Acad. Dermatol. 32(5 Pt 1), 711-716 (1995).
87. Barbareschi M, Murer B, Colby TV et al.: CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am. J. Surg. Pathol. 27(2), 141-149 (2003).
88. Lissak B, Vannetzel JM, Gallouedec N et al.: Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J. Endocrinol. Invest. 18(10), 813-816 (1995).
89. Bahrami S, Malone JC, Lear S, Martin AW: CD10 expression in cutaneous adnexal neoplasms and a potential role for differentiating cutaneous metastatic renal cell carcinoma. Arch. Pathol. Lab. Med. 130(9), 1315-1319 (2006).
90. Bodey B, Bodey B Jr, Kaiser HE: Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas. Anticancer. Res. 17(3C), 2343-2346 (1997).
91. Nowak MA, Guerriere-Kovach P, Pathan A et al.: Perianal Paget's disease: distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein-15 and cytokeratin 20 expression. Arch. Pathol. Lab. Med. 122(12), 1077-1081 (1998).
92. Battles OE, Page DL, Johnson JE: Cytokeratins, CEA, and mucin histochemistry in the diagnosis and characterization of extramammary Paget's disease. Am. J. Clin. Pathol. 108(1), 6-12 (1997).
93. Fetsch JF, Laskin WB, Miettinen M: Nerve sheath myxoma: a clinicopathologic and immunohistochemical ana lysis of 57 morphologically distinctive, S-100 protein-and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am. J. Surg. Pathol. 29(12), 1615-1624 (2005).
94. Fetsch JF, Laskin WB, Hallman JR, Lupton GP, Miettinen M: Neurothekeoma: an ana lysis of 178 tumors with detailed immunohistochemical data and long-term patient follow-up information. Am. J. Surg. Pathol. 31(7), 1103-1114 (2007). ■ A large series on neurothekeoma.
95. Page RN, King R, Mihm MC Jr, Googe PB: Microphthalmia transcription factor and NKI/C3 expression in cellular neurothekeoma. Mod. Pathol. 17(2), 230-234 (2004).
96. Plaza JA, Torres-Cabala C, Evans H, Diwan AH, Prieto VG: Immunohistochemical expression of S100A6 in cellular neurothekeoma: clinicopathologic and immunohistochemical ana lysis of 31 cases. Am. J. Dermatopathol. 31(5), 419-422 (2009).
97. Vered M, Carpenter WM, Buchner A: Granular cell tumor of the oral cavity: updated immunohistochemical profile. J. Oral. Pathol. Med. 38(1), 150-159 (2008).
98. Bellezza G, Colella R, Sidoni A et al.: Immunohistochemical expression of Galectin-3 and HBME-1 in granular cell tumors: a new finding. Histol. Histopathol. 23(9), 1127-1130 (2008).
99. Theaker JM, Fletcher CD: Epithelial membrane antigen expression by the perineurial cell: further studies of peripheral nerve sheath lesions. Histopathology 14(6), 581-592 (1989).
100. Folpe AL, Billings SD, McKenney JK et al.: Expression of claudin-1, a recently described tight junction-associated protein, distinguishes soft tissue perineurioma from potential mimics. Am. J. Surg. Pathol. 26(12), 1620-1626 (2002).
101. Yamaguchi U, Hasegawa T, Hirose T et al.: Sclerosing perineurioma: a clinicopathologic study of five cases and diagnostic utility of immunohistochemical staining for GLUT-1. Virchows Arch. 443(2), 159-163 (2003).
102. Chan J, Suster S, Wenig B et al.: Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am. J. Surg. Pathol. 21(2), 226-234 (1997).
103. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS: Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Am. J. Dermatopathol. 28(2), 99-104 (2006).
104. Calder KB, Coplowitz S, Schlauder S, Morgan MB: A case series and immunophenotypic ana lysis of CK20-/CK7+ primary neuroendocrine carcinoma of the skin. J. Cutan. Pathol. 34(12), 918-923 (2007).
105. Beer TW: Merkel cell carcinomas with CK20 negative and CK7 positive immunostaining [Letter to the Editor]. J. Cutan. Pathol. 36(3), 385-386 (2009).
106. Ralston J, Chiriboga L, Nonaka D: MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. Mod. Pathol. 21(11), 1357-1362 (2008).
107. Emile JF, Weschler J, Brousse N et al.: Langerhans cell histiocytosis: definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am. J. Surg. Pathol. 19(6), 636-641 (1995).
108. Talanin NY, Smith SS, Shelley ED, Moores WB: Cutaneous histiocytosis with Langerhans cell features induced by scabies: a case report. Pediatr. Dermatol. 11(4), 327-330 (1994).
109. Lau SK, Chu PG, Weiss LM: Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am. J. Surg. Pathol. 32(4), 615-619 (2008).
110. Rezk SA, Spagnolo DV, Brynes RK, Weiss LM: Indeterminate cell tumor: a rare dendritic neoplasm. Am. J. Surg. Pathol. 32(12), 1868-1876 (2008).
111. Kurtin PJ, Pinkus GS: Leukocyte common antigen: a diagnostic discriminant between hematopoietic and non-hematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. Hum. Pathol. 16(4), 353-365 (1985).
112. Cartun RW, Coles FB, Pastuszak WT: Utilization of monoclonal antibody L26 in the identification and confirmation of B-cell lymphomas: a sensitive and specific marker applicable to formalin- and B5-fixed, paraffin-embedded tissues. Am. J. Pathol. 129(4), 415-421 (1987).
113. Balmer NN, Hughey L, Busam KJ, Reddy V, Andea AA: Primary cutaneous peripheral T-cell lymphoma with aberrant coexpression of CD20: case report and review of the literature. Am. J. Dermatopathol. 31(2), 197-192 (2009).
114. Blakolmer K, Vesely M, Kummer JA et al.: Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T (NK/T-) cell lymphomas. Mod. Pathol. 13(7), 766-772 (2000).
115. Hiraga J, Tomita A, Sugimoto T et al.: Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113(20), 4885-4893 (2009).
116. Mason DY, Cordell JL, Brown MH: CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 86(4), 1453-1459 (1995).
117. Chu PG, Arber DA: CD79a: a review. Appl. Immunohistochem. Mol. Morphol. 9(2), 97-106 (2001).
118. Hoefnagel JJ, Mulder MM, Dreef E et al.: Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Mod. Pathol. 19(9), 1270-1276 (2006).
119. Dong HY, Browne P, Liu Z, Gangi M: PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation. Histopathology 53(3), 278-287 (2008).
120. Hoefnagel JJ, Dijkman R, Basso K et al.: Distinct types of primary cutaneous B-cell lymphoma identified by gene expression profiling. Blood 105(9), 3671-3678 (2005).
121. Hoefnagel JJ, Vemeer MH, Jansen PM et al.: Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br. J. Dermatol. 149(6), 1183-1191 (2003).
122. De Leval L, Harris NL, Longine J, Ferry JA, Duncan LM: Cutaneous B-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2 and CD21 in differential diagnosis and classification. Am. J. Surg. Pathol. 25(6), 732-741 (2001). ■■ A helpful panel in diagnosing cutaneous B-cell infiltrate.
123. Chilosi M, Adami F, Lestani M et al.: CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod. Pathol. 12(12), 1101-1106 (1999).
124. Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED: Novel immunophenotypic feature of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Mod. Pathol. 22(6), 807-816 (2009).
125. Yatabe Y, Suzuki R, Tobinai K et al.: Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95(7), 2253-2261 (2000).
126. Reed JC: Bcl-2 and the regulation of programmed cell death. J. Cell. Biol. 124(2), 1-6. (1994).
127. Cerroni L, Volkenandt M, Rieger E, Soyer HP, Kerl H.: Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J. Invest. Dermatol. 102(2), 231-235 (1994).
128. Bailey EM, Ferry JA, Harris NL et al.: Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am. J. Surg. Pathol. 20(8), 1011-1023 (1996).
129. Goodlad JR, Krajewski AS, Batstone PJ et al.: Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am. J. Surg. Pathol. 26(6), 733-741 (2002).
130. Kim BK, Surti U, Pandya A, Cohen J, Rabkin MS, Swerdlow SH: Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence situ hybridization ana lysis of primary and secondary cutaneous follicular lymphomas. Am. J. Surg. Pathol. 29(1), 69-82 (2005).
131. Servitje O, Gallardo F, Estrach T et al.: Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br. J. Dermatol. 147(6), 1147-1158 (2002).
132. Levy R, Warnke R, Dorfman RF et al.: The monoclonality of human B-cell lymphomas. J. Exp. Med. 145(4), 1014-1028 (1977).
133. Ralfkiaer E, Wantzin GL, Mason DY, Hou-Jensen K, Stein H, Thomsen K: Phenotypic characterization of lymphocyte subsets in mycosis fungoides: comparison with large plaque parapsoriasis and benign chronic dermatoses. Am. J. Clin. Pathol. 84(5), 610-619 (1985).
134. Michie SA, Abel EA, Hoppe RT, Warnke RA, Wood GS: Expression of T-cell receptor antigens in mycosis fungoides and inflammatory skin lesions. J. Invest. Dermatol. 93(1), 116-120 (1989).
135. Ormsby A, Bergfeld WF, Tubbs RR, Hsi ED: Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community clinical practice. J. Am. Acad. Dermatol. 45(3), 405-413 (2001).
136. Vonderheid EC, Bigler RD, Kotecha A et al.: Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sezary syndrome). J. Invest. Dermatol. 117(3), 654-662 (2001).
137. Murphy M, Fullen D, Carlson JA: Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. Am. J. Dermatopathol. 24(1), 6-16 (2002).
138. Ortonne N, Buyukbabani N, Delfau-Larue MH, Bago M, Wechsler J: Value of the CD8-CD3 ratio for the diagnosis of mycosis fungoides. Mod. Pathol. 16(9), 857-862 (2003).
139. Kamarashev J, Burg G, Kempf W, Hess Schmid M, Dummer R: Comparative ana lysis of histological and immunohistological features in mycosis fungoides and Sezary syndrome. J. Cutan. Pathol. 25(8), 407-412 (1998).
140. Lu D, Patel KA, Duvic M, Jones D: Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J. Cutan. Pathol. 29(8), 465-472 (2002).
141. + cutaneous T-cell lymphoma with pagetoid epidermotropism and angiocentric and angiodestructive infiltration. Arch. Dermatol. 126(6), 801-804 (1990).
142. Whittam LR, Calonje E, Orchard G, Fraser-Andrews EA, Woolford A, Russell-Jones R: CD-8 positive juvenile onset mycosis fungoides: an immunohistochemical and genotypic ana lysis of six cases. Br. J. Dermatol. 143(6), 1199-1204 (2000).
143. Wieczorek R, Buck D, Bindl J, Knowles DM: Monoclonal antibody Leu-22 (L60) permits the demonstration of some neoplastic T cells in routinely fixed and paraffin-embedded tissue sections. Hum. Pathol. 19(12), 1434-1443 (1988).
144. Said JW, Stoll PA, Shintaku P et al.: Leu-22: a preferential marker for T-lymphocytes in paraffin-embedded sections: staining profile in T- and B-cell lymphomas, Hodgkin's disease, other lymphoproliferative disorders, myeloproliferative diseases, and various neoplastic processes. Am. J. Clin. Pathol. 91(5), 542-549 (1989).
145. Takeshita M, Akamatsu M, Ohshima K et al.: Angiocentric immunoproliferative lesions of the skin show lobular panniculitis and are mainly disorders of the larger granular lymphocytes. Hum. Pathol. 26(12), 1321-1328 (1995).
146. Natkunam Y, Smoller BR, Zehnder JL et al.: Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am. J. Surg. Pathol. 23(5), 571-581 (1999).
147. Massone C, Chott A, Metze D et al.: Subcutaneous, blastic natural killer (NK) NK/T-cell and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic and molecular study of 50 patients. Am. J. Surg. Pathol. 28(6), 719-735 (2004).
148. Chang SE, Huh J Choi JH et al.: Clinicopathological features of CD56+ nasal-type T/natural killer cell lymphomas with lobular panniculitis. Br. J. Dermatol. 142(5), 924-930 (2000).
149. Felgar RE, MacOn WR, Kinney MC et al.: TIA-1 expression in lymphoid neoplasms: identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am. J. Pathol. 150(6), 1893-1900 (1997).
150. Schwartz EJ, Molina-Kirsch H, Zhao S, Marinelli RJ, Warnke RA, Natkunam Y: Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an ana lysis of 84 cases. Am. J. Clin. Pathol. 130(3), 343-351 (2008).
151. Bittencourt AL, Barbosa HS, Vieira MD, Farre L: Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases. Acta. Oncol. 48(4), 598-604 (2009).
152. Schwarting R, Gerdes J, Durkop H et al.: BER-H2: a new anti Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74(5), 1678-1689 (1989).
153. +) anaplastic large cell lymphomas: morphologic, immunohistologic and clinical characteristics. Am. J. Pathol. 135(2), 359-367 (1989).
154. Kadin M, Nasu K, Sako D et al.: Lymphomatoid papulosis: a cutaneous proliferation of activated helper T cells expression Hodgkin's disease-associated antigens. Am. J. Pathol. 119(2), 315-325 (1985).
155. Cepeda LT, Pieretti M, Chapman SF, Horenstein MG: CD30-positive atypical lymphoid cells in common non-neoplastic cutaneous infiltrates rich in neutrophils and eosinophils. Am. J. Surg. Pathol. 27(7), 912-918 (2003).
156. Cerroni L, Rieger E, Hodl S, Kerl H: Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am. J. Surg. Pathol. 16(6), 543-552 (1992).
157. Vergier B, De Muret A, Beylot-Barry M et al.: Transformation of mycosis fungoides: clinicopathologic and prognostic features of 45 cases. Blood 95(7), 2212-2218 (2000).
158. Werner B, Massone C, Kerl H, Cerroni L: Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J. Cutan. Pathol. 35(12), 1100-1107 (2008).
159. Perkins SL, Pickering D, Lowe EJ et al.: Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridization: a genetic and pathological correlation. Br. J. Haematol. 131(5), 624-627 (2005).
160. Yamaguchi T, Oshima K, Karube K et al.: Expression of chemokines
161. Maeda K, Matsuda M, Suzuki H, Saitoh HA: Immunohistochemical recognition of human follicular dendritic cells (FDCs) in routinely processed paraffin sections. J. Histochem. Cytochem. 50(11), 1475-1486 (2002).
162. Said JW, Shintaku IP, Parekh K, Pinkus GS: Specific phenotyping of T-cell proliferations in formalin-fixed paraffin-embedded tissues. Use of antibodies to the T-cell receptor b F1. Am. J. Clin. Pathol. 93(3), 382-386 (1990).
163. Al Gwaiz LA, Bassinoi W: Immunophenotyping of acute lymphoblastic leukemia using immunohistochemistry in bone marrow specimens. Histol. Histopathol. 23(10), 1223-1228 (2008).
164. Buresh CJ, Oliai BR, Miller RT: Reactivity with TdT in Merkel cell carcinoma: a potential diagnostic pitfall. Am. J. Clin. Pathol. 129(6), 894-898 (2008).
165. Kaddu S, Zenahlik P, Beham-Schmid C, Kerl H, Cerroni L: Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. J. Am. Acad. Dermatol. 40(6), 966-978 (1999).
166. Cibull TL, Thomas AB, O'Malley DP, Billings SD: Myeloid leukemia cutis: a histologic and immunohistochemical review. J. Cutan. Pathol. 35(2), 180-185 (2008).
167. Greaves MF, Brown J, Molgaard HV et al.: Molecular features of CD34: a hematopoietic progenitor cell-associated molecule. Leukemia 1(6 Suppl.), 31-36 (1992).
168. Pulford KA, Rigeny EM, Micklem KJ et al.: Kp-1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J. Clin. Pathol. 42(4), 414-421 (1989).
169. Facchetti F, Bertalot G, Grigolato PG: Kp-1 (CD68) staining of malignant melanomas. Histopathology 19(2), 141-145 (1991).
170. Lau SK, Chu PG, Weiss LM: CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am. J. Clin. Pathol. 122(5), 794-801 (2004).
171. Horny HP, Sillaber C, Menke D et al.: Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 22(9), 1132-1140 (1998).
172. Wollenberg A, Wagner M, Gunther S et al.: Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. 119(5), 1096-1102 (2002).
173. +) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am. J. Surg. Pathol. 29(10), 1274-1283 (2005).
174. Natkunam Y, Rouse RV: Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow. Am. J. Surg. Pathol. 24(1), 81-91 (2000).